

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE IN RELATION TO
THE UNITED STATES OF AMERICA**

This announcement is made by OrbusNeich Medical Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders and potential investors of the Company with the latest business update of the Group.

The board (“**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on September 25, 2023, the Group and Cardiovascular Systems, Inc. (“**CSI**”), a subsidiary of Abbott Laboratories (NYSE: ABT) (“**Abbott**”), entered into an amendment to distribution agreement (the “**Agreement**”) pursuant to which both parties agreed the term of the Group’s appointment of CSI as the exclusive distributor of coronary and peripheral balloon products of the Group in the territory of the United States of America will be extended until December 31, 2027.

CSI is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. CSI’s products include peripheral orbital atherectomy systems, coronary orbital atherectomy systems, crowns, and accessories. It markets its products through its direct sales force in the United States of America to hospitals and clinics. CSI is headquartered in St. Paul, Minnesota, the United States of America. To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, CSI and its ultimate beneficial owner are third parties independent of the Company and of connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company.

The entry into the Agreement underscores the Group's strengthened alliance with CSI, especially following its strategic acquisition by Abbott in early 2023. The United States of America market has been one of the key revenue growth drivers of the Group since 2022. The Board believes that, with Abbott's extensive network and presence in the United States of America, CSI will be able to access broader spectrum of hospitals and heart centres across the United States of America. This collaboration will accelerate the market penetration of the Group's products in the United States of America market and will help the Group realise continuous growth, and ultimately create greater value for the shareholders.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN

Chairman, Executive Director and Chief Executive Officer

Hong Kong, September 27, 2023

As at the date of this announcement, the Board of the Company comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ching Chung John CHOW, Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.